Product image of Migsun (Naproxen Sodium, Sumatriptan Succinate) supplied by GNH India

Migsun

Active Ingredient:
Naproxen Sodium, Sumatriptan Succinate
Origin:
EU

Migsun (Naproxen Sodium, Sumatriptan Succinate)

Naproxen sodium and sumatriptan succinate, the active ingredients in Migsun, are an NSAID and a selective 5‑HT1B/1D receptor agonist presented as an oral tablet for the acute treatment of migraine attacks in adults. The combination provides anti‑inflammatory pain relief together with cranial vasoconstriction to alleviate migraine symptoms.

GNH India supplies Migsun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and regulatory compliance for global distribution, with reliable logistics, post‑market support, and technical assistance.

Manufacturer / TM Owner

Orion Corporation

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Migsun combines an NSAID and a triptan to target migraine pathophysiology.

  • Migraine attack: rapid relief of headache pain and associated symptoms.
  • Migraine with aura: reduction of headache intensity and associated neurological symptoms.
  • Acute episodic migraine: prevention of progression to severe pain when taken early.

How It Works

  • Naproxen sodium inhibits cyclooxygenase‑1 and‑2 enzymes, decreasing prostaglandin synthesis and reducing inflammation and pain. Sumatriptan succinate selectively activates 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings, producing vasoconstriction and blocking pain signal transmission, together providing prompt migraine relief.

Side Effects

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Dizziness: transient light‑headedness.
  • Dry mouth: reduced salivation.
  • Fatigue: feeling of tiredness.
  • Abdominal pain: discomfort in the stomach area.
  • Tingling sensation: paresthesia in extremities.

Serious or Rare Side Effects

  • Chest pain: possible cardiac ischemia.
  • Serotonin syndrome: agitation, hyperthermia, muscle rigidity.
  • Severe allergic reaction: rash, swelling, anaphylaxis.
  • Cardiovascular events: stroke or myocardial infarction.
  • Severe hypertension: sudden rise in blood pressure.
  • Hepatic dysfunction: elevated liver enzymes.

Precautions & Warnings

Before prescribing Migsun, consider the following precautions:

  • Cardiovascular assessment: evaluate risk of ischemic heart disease.
  • Concomitant MAO inhibitors: avoid use within 14 days of MAOI therapy.
  • Serotonin syndrome monitoring: watch for signs when combined with serotonergic agents.
  • Renal or hepatic impairment: adjust use based on organ function.
  • Uncontrolled hypertension: contraindicated in severe high blood pressure.
  • Store at room temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Migsun may interact with several drug classes.

Major Interactions (Avoid)

  • MAO inhibitors: risk of severe hypertension and serotonin syndrome.
  • Other triptans: additive vasoconstriction leading to cardiovascular events.
  • SSRIs/SNRIs: increased risk of serotonin syndrome.
  • Anticoagulants/antiplatelet agents: heightened bleeding risk from naproxen.
  • CYP2D6 inhibitors: may raise sumatriptan plasma levels.

Moderate Interactions (Monitor Closely)

  • Antihypertensives: possible reduction in blood pressure control.
  • Diuretics: may affect electrolyte balance.
  • Additional NSAIDs: increased gastrointestinal toxicity.
  • Oral contraceptives: potential for reduced efficacy.
  • Lithium: enhanced lithium toxicity risk.

Frequently Asked Questions

Migsun is a prescription oral tablet that combines naproxen sodium and sumatriptan succinate for the acute treatment of migraine attacks in adults. The formulation targets both inflammation and vascular mechanisms to provide rapid relief of headache and associated migraine symptoms.

Naproxen sodium is a non‑steroidal anti‑inflammatory drug that blocks cyclooxygenase‑1 and ‑2 enzymes, reducing the production of prostaglandins that cause inflammation, pain, and fever. In the Migsun combination, it contributes anti‑inflammatory and analgesic effects that complement the triptan component.

The specific dose of Migsun is determined by the prescribing clinician based on the patient’s medical condition, severity of migraine, and other individual factors. Healthcare professionals select the appropriate tablet strength and dosing schedule in accordance with local prescribing guidelines.

The safety of Migsun in pregnancy or while breastfeeding has not been established. Healthcare providers should weigh potential risks and benefits before prescribing it to pregnant or nursing women, and alternative therapies may be considered when appropriate.

To order Migsun, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Migsun combines an NSAID with a triptan, offering both anti‑inflammatory pain relief and targeted cranial vasoconstriction. Compared with single‑agent triptans, it may provide faster and more comprehensive symptom control, while the NSAID component can reduce reliance on additional analgesics.

Migsun tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Migsun is taken orally with a full glass of water. It is usually administered at the first sign of a migraine attack, as directed by a healthcare professional, and should not be taken more than the prescribed number of tablets in a 24‑hour period.

Serious risks include cardiovascular events such as chest pain, myocardial infarction, or stroke, especially in patients with underlying heart disease, as well as serotonin syndrome when combined with other serotonergic drugs, and severe allergic reactions that may require immediate medical attention.

Migsun should not be used by individuals with known hypersensitivity to naproxen, sumatriptan, or any component of the formulation, patients with uncontrolled hypertension, recent myocardial infarction or stroke, and those taking MAO inhibitors within the past 14 days.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Naproxen Sodium, Sumatriptan Succinate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT